Key facts - Bristol Myers Squibb

Chief Executive Officer:

Headquarters:

Princeton, New Jersey

Business:

Biopharmaceuticals

Web address:

NYSE listing:

BMY

Total revenues:

$45 billion in 2023

R&D investment:

$9.3 billion in 2023, which included the discovery and development of new medicines for patients

2023 Worldwide revenues:

ELIQUIS^®(apixaban), $12.2 billion

OPDIVO^®(nivolumab), $9 billion

REVLIMID® (lenalidomide), $6.1 billion

ORENCIA^®(abatacept), $3.6 billion

POMALYST® / Imnovid® (pomalidomide), $3.4 billion

YERVOY® (ipilimumab), $2.2 billion

SPRYCEL^®(dasatinib), $1.9 billion

REBLOZYL® (luspatercept-aamt), $1.0 billion

ABRAXANE^®(paclitaxel protein-bound particles for injectable suspension) (albumin-bound), $1.0 billion

OPDUALAG™(nivolumab and relatlimab-rmbw): $627 million

ABECMA^® (idecabtagene vicleucel), $472 million

ZEPOSIA® (ozanimod), $434 million

BREYANZI® (lisocabtagene maraleucel), $364 million

CAMZYOS® (mavacamten), $231 million

SOTYKTU™(deucravacitinib), $170 million

ONUREG® (azacitidine tablets), $168 million

INREBIC® (fedratinib), $110 million

AUGTYRO™ (repotrectinib), $1 million

Mature and other products* $1.9 billion

*Includes products that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue.

Please click on the product links to see the Full Prescribing Information for ABECMA^®, ABRAXANE^®, AUGTYRO™, BREYANZI^®, CAMZYOS^® ELIQUIS^®, INREBIC^®, ONUREG^®, OPDIVO^®, OPDUALAG^™, ORENCIA^®, POMALYST^® , REBLOZYL^®, REVLIMID^® , SOTYKTU^™ , SPRYCEL^® , YERVOY^® and ZEPOSIA^® including Boxed WARNINGS for ABECMA^®, ABRAXANE^®, BREYANZI^®, CAMZYOS^®, ELIQUIS^®, INREBIC^®, POMALYST^®, REVLIMID^®, and Boxed WARNINGS for YERVOY^® regarding immune-mediated adverse reaction.

Updated October 2024